Portfolio News January 23, 2020 Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Bay City Capital News January 7, 2020 Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing -in-Class Therapeutics in Fibrosis and Cancer
Bay City Capital News December 10, 2019 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
Uncategorized September 25, 2019 Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
Portfolio News August 27, 2019 Synchronicity Pharma Highlights New Research Demonstrating Beneficial Effects of Modulating Core Clock Proteins in Glioblastoma Stem Cells
Portfolio News June 27, 2019 Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
Portfolio News October 12, 2018 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
Bay City Capital News June 29, 2018 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis
Portfolio News February 14, 2018 Twist Bioscience Launches Exome and Custom Target Enrichment Solutions for Genomics and Clinical Researchers Conducting Next-Generation Sequencing
Bay City Capital News January 25, 2018 Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock
Portfolio News January 4, 2018 Madrigal: This Year’s Best Midcap Stock Was Virtually Unknown 6 Months Ago